Price
No data yet.
Social Signal Score
Revenue
$7.03B+77.58%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Charl van Zyl
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 5,214
- Beta
- 0.26
- Country
- DK
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 2.34
Financials
Revenue
$7.03B+77.6%Net Income
$1.66B+339.1%EBITDA
$2.84B+185.2%Free Cash Flow
$483.50M+7.0%EPS (diluted)
$1.67+339.5%Shares Outstanding (diluted)
992.40M-0.1%Operating Expenses
$3.47BCash & Debt
$1.96BReturn of Capital
$1.14BDividend per Share
$0.18Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $24.30B | $3.18B | $3.21 |
| 2024 | $22.00B | $3.14B | $3.17 |
| 2023 | $19.91B | $2.29B | $2.31 |
| 2022 | $18.25B | $1.92B | $1.93 |
| 2021 | $16.30B | $1.32B | $1.33 |
| 2020 | $17.67B | $1.58B | $7.96 |
| 2019 | $17.36B | $2.31B | $11.64 |
| 2018 | $17.88B | $3.91B | $19.67 |
| 2017 | $17.23B | $2.62B | $13.28 |
| 2016 | $15.63B | $1.21B | $6.14 |
| 2015 | $14.59B | $-5.69B | $-28.98 |
| 2014 | $13.47B | $-153.00M | $-0.78 |
| 2013 | $15.26B | $855.00M | $4.36 |
| 2012 | $14.80B | $1.17B | $5.94 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from HLBBF's reported EPS growth of -4.6% a year over 13 years.
- EPS in 5 years
- $2.54
- Implied price
- $35.51
- Return from $6.64
- 39.8% a year
To earn 15.0% a year on these assumptions you'd need to buy at $17.66 — today's price is already 62.4% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 10 | 12 | 14 | 16 | 18 |
|---|---|---|---|---|---|
| -14.6% | 17.0% | 21.4% | 25.2% | 28.6% | 31.6% |
| -9.6% | 23.9% | 28.5% | 32.5% | 36.1% | 39.3% |
| -4.6% | 30.7% | 35.6% | 39.8% | 43.6% | 47.1% |
| 0.4% | 37.6% | 42.7% | 47.2% | 51.2% | 54.8% |
| 5.4% | 44.4% | 49.8% | 54.5% | 58.7% | 62.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
120Social Signal Score
Mentions (1)
- Newsseekingalpha.com·5h ago·Positive
H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript H. Lundbeck A/S (HLBBF) Q2 2026 Earnings Call Transcript
View source ↗
Earnings
Wed, Nov 11(in 3 months)
Consensus estimate $0.18 per share
Typical surprise +19.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 19$0.18 vs $0.17beat
- Tue, May 12$0.26 vs $0.22beat
- Tue, Feb 3$0.01 vs $0.11miss
- Tue, Nov 11$0.17 vs $0.14beat
- Tue, Aug 12$0.15 vs $0.15beat
- Wed, May 14$0.17 vs $0.13beat
Estimates and results for HLBBF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.